Forging partnerships with leading institutions.
Elysium partners with prominent academic institutions and universities to support scientific research and advance health.
From the Harvard T.H. Chan School of Public Health to the Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences at Oxford, our partnerships allow us to break new ground in aging research and develop compounds that improve human healthspan.
Harvard and the Microbiome
Elysium is collaborating with Harvard University on a multi-year agreement to fund research projects focused on cellular function and other key modulators in the aging process. Elysium is only the eighth company to be invited to partner with Harvard in this way.
The first project is being led by Wendy Garrett, professor of Immunology and Infectious Diseases at Harvard T. H. Chan School of Public Health. The goal is to better understand the relationship between the gut microbiome and overall health, and in particular the role of NAD+.
Collaborating with Pharmaceutical Companies at Cambridge
Elysium is working with the University of Cambridge and the Milner Therapeutics Institute to discover and develop preventative medicines from natural products. This elite program fosters collaborations between academia and industry to accelerate medical advancements.
Other members include AstraZeneca, Astex, GSK, MedImmune, Otsuka, Pfizer, and Shionogi. Elysium is the only consumer-facing company unanimously invited to join this consortium of leading pharmaceutical companies.
The Oxford-Elysium Fellowship Program
At Oxford University, Elysium has established the Oxford-Elysium Fellowship program, which recruits the best researchers to work in cutting-edge laboratories relating to cellular aging. The first fellow, Hanlin Zhang, discovered a new pathway for autophagy induction, which may play a significant role in aging.
Zhang will work in the lab of Katja Simon, Professor of Immunology in the Kennedy Institute of Rheumatology in the Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences. Elysium owns first rights to all intellectual property developed by the fellow.